SHANGHAI, Sept. 28,
2024 /PRNewswire/ -- Sanyou Bio recently celebrated a
prestigious move into its new 10,000-square-meter R&D building
at Shanghai headquarters. This is
not just a change in physical location, but a qualitative leap in
the company infrastructure. It marks a solid step forward for
Sanyou Bio to accelerate the development of innovative biologics
and advance its mission to serve the global biopharmaceutical
industry. As the core of Sanyou Bio's global strategy, the
Shanghai headquarters integrates
both an operational center with a high-level R&D hub. It will
lay a solid foundation for attracting top talents, absorbing
cutting-edge technology, and expanding into international markets,
opening a new chapter in global development.
Founded in 2015, Sanyou Bio is a globally leading national
high-tech enterprise focusing on innovative biopharmaceutical
R&D and services. The company is committed to solving the
'R&D challenges' of innovative biologics. Starting from
molecule discovery, Sanyou Bio has built a world-class
trillion-level molecule library and developed a trillion-level
innovative biopharmaceutical discovery platform around the molecule
library. The company has also established 4C comprehensive business
system, integrating 'Differentiated CRO, Integrated CDO,
Collaborative CPO, and Specialized CRS'. This approach offers
end-to-end solutions for innovative biologics R&D and promote
the innovative development of the biopharmaceutical industry.
The launch of the new 10,000-square-meter R&D building marks
another significant leap in the development of Sanyou Bio. It
symbolizes a comprehensive upgrade in the company infrastructure,
including core technology, base construction, hardware facilities,
R&D strength, and qualification system. This leap also provides
strong support for accelerating Sanyou Bio's globalization strategy
and deepening international collaboration and exchange.
Sanyou Bio Development Review Part 1: Core Technology
Core Technology Platform: Super Trillion Innovative Biologics
Discovery Platform
In order to fulfill the mission of 'to make it easy to discover
innovative biological drugs anywhere', Sanyou Bio started from
addressing the challenges of discovering innovative biologic
molecules. After 9 years of continuous innovation, the company has
established a core technology platform for innovative
biopharmaceutical discovery, with a trillion-level molecule library
at its core.
This platform, fully owned by Sanyou Bio, boasts a globally
leading trillion-level molecule library with top indicators. The
library covers more than ten types of molecules, including fully
human monoclonal antibodies, nanobodies, mouse monoclonal
antibodies, rabbit monoclonal antibodies, bispecific antibodies,
fusion proteins, targeted peptides, and targeted small proteins. It
enables the rapid and highly successful identification of candidate
molecules with high affinity, excellent specificity, and good
developability. The platform can be widely applied in the fields
such as innovative drug discovery, diagnostics, detection, and
scientific research antibody customization and systematically solve
the challenges of discovering antibody macromolecules against
difficult targets like GPCRs.
Supporting Platform 1: Innovative Biologics Integrated R&D
Platform
In order to deepen the R&D of innovative biologic drug
discovery and achieve the leap from target identification to
clinical application, Sanyou Bio has developed an integrated
R&D platform from target to PCC molecule, from PCC molecule to
IND application, and from IND application to clinical sample
production. This platform covers ten key modules, including raw
material preparation, antibody generation, in vitro screening,
antibody engineering, animal model, developability analysis, cell
line development, process development, quality control, and pilot
production. The platform includes 50+ sub-platforms and several
specialized platforms. It has helped obtain IND approvals for 8 CPO
projects and multiple comprehensive service projects, with a
cumulative experience of discovering 300+ antibody drugs. We have
developed 150+ in vitro functional screening methods, 20+ primary
cell models, 300+ animal models, and 50+ developability analysis
methods. Additionally, Sanyou Bio has established 700+ quality
document supports with outstanding refined R&D
capabilities.
Supporting Platform 2: Innovative Biologics AI Discovery
Platform
To expand the application areas of innovative molecules and
improve the intelligence level of innovative biopharmaceutical
discovery, Sanyou Bio has built an intelligent R&D platform for
innovative biologics. The intelligent platform encompasses key
modules such as structural simulation and molecular docking,
AI-based drug design, AI-based drug optimization, bioinformatics,
and project management automation. It has created an innovative
intelligent R&D platform for biologics that integrates
"digitalization + computation (AI-driven drug development) +
automation". The platform integrates drug R&D digital
capabilities by connecting full-process and full-factor,
incorporating big data middle platform, and offering a
fast-delivery front desk. It merges bioinformatics, computational
science, and statistics to establish comprehensive computational
biology capabilities. Furthermore, the platform combines automation
technology with drug screening techniques to form comprehensive
automation technology capabilities.
Sanyou Bio Development Review Part 2: Infrastructure and
Facilities
Base Construction: Establishing a strong foundation in
China, aligning with global
strategy
The 10,000-square-meter R&D building at Shanghai headquarters, as the core engine of
Sanyou Bio global strategy, stands proudly on the bank of the
Huangpu River, about 10 kilometers south of the Oriental Pearl
Tower. It has convenient transportation and prime location in the
heart of a world-class biopharmaceutical industry cluster. This
nine-story building, with each floor meticulously designed to be
about 1,200 square meters, and a total area of about 10,500 square
meters. It is an innovative drug R&D center that integrates
modern, intelligent, and eco-friendly concepts. The interior design
is ingenious, focusing on the flexible spaces and separation of
dynamic and quiet areas, while also taking into account
personalized needs. This provides an efficient and comfortable
working environment for researchers. Here, green health coexists
with openness and freedom, inspiring every researcher with creative
innovation.
In addition to the R&D building, Sanyou Bio has established
a pilot production base of over 5,000 square meters through both
self-construction and integration to accelerate the clinical
transformation of innovative molecules. The pilot plant follows the
international high-standard for pilot production processes to
ensure that scientific research results can be smoothly and
successfully translated into tangible products, providing strong
support for the company's global layout.
Sanyou Bio has established multiple overseas R&D offices or
business hubs in global biopharmaceutical innovation centers such
as Philadelphia, Boston, San
Diego in the United States,
and London in the United Kingdom. These hubs serve not only as
bridges for close collaboration with international clients and
suppliers, but also as key windows for the company to absorb
cutting-edge global technologies and expand international market
presence. Through these hubs, Sanyou Bio can keep abreast of the
latest developments in the global biopharmaceutical field in real
time, maintain close partnerships with top research institutions
and companies worldwide, and jointly promote the innovation in the
biopharmaceutical industry.
Hardware Facilities: 1,200+ advanced equipment, driving a new
leap in R&D capabilities
Sanyou Bio has established an integrated R&D laboratory for
innovative biologics, which is centered on advanced and
comprehensive facilities and equipment, and fully covers the entire
process needs of biologic drug development. The highlight of the
laboratory is its extensive equipment lineup, with a total of over
1,200 units and an investment of over 15
million USD in facilities and equipment, ranging from basic
to cutting-edge experimental equipment.
Among these are high-value, cutting-edge equipment groups,
including automated antibody library screening systems, multicolor
flow cytometry analyzers, SPR and BLI affinity kinetic analysis
systems, single-cell printing and imaging devices, mammalian cell
culture bioreactors, AKTA purification systems and lyophilized
preparation equipment, high-performance and ultra-high-performance
liquid chromatography analyzers, as well as capillary
electrophoresis and content analysis systems. These advanced
equipment sets, worth millions of US dollars, provide solid
hardware support for the rapid advancement of scientific research
projects.
With these cutting-edge laboratory equipment, Sanyou Bio has not
only accelerated the R&D process of biological drugs, but also
enhanced the quality and efficiency of its R&D capabilities. In
the future, Sanyou Bio will continue to increase its investment,
introduce more advanced equipment and technologies, and contribute
further to the development of the biopharmaceutical industry.
Sanyou Bio Development Review Part 3: Business Case Studies
4C Comprehensive Business Model: Accelerating the
Multidimensional R&D Process of Innovative Biopharmaceutical
Molecules
Sanyou Bio has launched the '4C' comprehensive business model to
fully leverage the value of its trillion-level innovative biologics
discovery platform for tens of thousands of companies engaged in
the development of diagnostic products and millions of
professionals engaged in life science and pharmaceutical R&D
around the world. The model drives drug discovery and development
services (CRO/CDO businesses) with technological innovation,
product innovation, long-term capability enhancement, and
efficiency improvements. It supports early-stage research projects
that fill the unmet gaps in human disease markets, tackling
diseases with no drug or suboptimal treatment options (CPO
business). Additionally, it offers high-quality branded reagents to
provide essential resources for new drug R&D (CRS business).
The '4C' comprehensive business covers multiple indications such as
cancer and infectious diseases.
IND Cases: Successfully assisted 8 CPO projects in obtaining
clinical approval
As of September 2024, Sanyou Bio
has assisted 8 CPO projects to obtain clinical approval
Sanyou Bio has successfully screened innovative biologic drug
molecules from its super-trillion molecule library that have
entered clinical trials. These molecules are of a wide variety,
including fully human monoclonal antibodies, bispecific antibodies,
and nanobodies, related to therapeutic approaches such as CAR-T,
TAC-T, and ADC. This diversity provides clients with diversified
drug development options.
Client Collaboration: Served and collaborated with 1,200+ global
clients to explore new business frontiers
Sanyou Bio has laid out its future with a global vision and has
successfully established a cross-border collaboration network,
partnering with over 1,200 top clients worldwide. Our business
footprint extends to many key global markets in the US,
Europe, and China, with operation hubs in major cities
such as Boston, Philadelphia, San
Diego, and London. Through
these strategic locations, we provide seamless, efficient,
convenient, and customized services to our global clients.
Our strong lineup of partners includes world-renowned
pharmaceutical giants, cutting-edge drug R&D institutions, and
innovative diagnostic reagent companies. These industry leaders
have established deep and lasting collaborations with Sanyou Bio.
Based on a common vision and ambition, we continue to explore and
innovate in the vast biopharmaceutical landscape, collectively
promote the progress and development of the industry, and create
new milestones in our business ventures.
Sanyou Bio Development Review Part 4: Innovative R&D
Patent Accumulation: 110+ Patents ensure a steady path of
innovation
As of September 2024, Sanyou Bio
has continued to develop and applied for more than 110 patents, of
which more than 20 have been authorized.
The achievement of these patent results not only serves as a
high recognition of Sanyou Bio's continuous innovation
capabilities, but also solidifies its leading position in the field
of biopharmaceuticals. These patents act as strong intellectual
property fortresses, providing robust legal support for the
company's long-term strategic planning. Additionally, they have
secured a valuable first-mover advantage and core competitiveness
for the company in the fiercely competitive global market.
Academic Influence: 50+ High-impact papers, demonstrating
profound academic background
As of September 2024, Sanyou Bio
and its collaborative clients have published more than 59
high-impact papers, including 24 articles published in top journals
with an IF greater than 10, such as Science, Cell Research, Cell
Discovery, along with their sub-journals. Notably, one of these
articles was featured on the cover of Small Methods journal.
Research Projects: Won 17 funding awards and grants
As of September 2024, Sanyou Bio
has obtained 17 special scientific research funds and awards.
The award-winning projects span various cutting-edge fields,
from the honor of winning the title of Shanghai Science and
Technology 'Little Giant', to the recognition of the funding for
key projects in the Zhangjiang National Independent Innovation
Demonstration Zone. Additional accolades include talent-specific
rewards in key industry areas and support from the National Foreign
Trade and Economic Development Special Fund (Trade in Services).
Each honor represents a high recognition of Sanyou Bio's scientific
research and innovation capabilities.
Notably, Sanyou Bio not only independently undertakes a number
of major research projects, but also deeply integrates into the
national scientific research system as a partner company and
participates in national key R&D programs. In the fight against
COVID-19, the company actively engaged in the preclinical drug
R&D projects of fully human monoclonal neutralizing antibodies
and receptor fusion proteins, contributing Chinese strength to the
global pandemic response. Additionally, in the field of developing
new antibody drugs targeting the immunosuppressive microenvironment
of brain gliomas, Sanyou Bio has collaborated with major projects
in Chongqing focusing on
technological innovation and application development. Together,
they explored new frontiers in biomedicine and brought hope to
patients worldwide.
The successful participation in these scientific research
projects has significantly enhanced Sanyou Bio's R&D
capabilities and international influence, while injecting new
vitality and insight into the field of global biopharmaceuticals.
It highlights the responsibility and commitment of Chinese
companies in global research collaboration.
Sanyou Bio Development Review Part 5: Qualification and
Certification
Qualifications: 6 Certifications + 2 System Accreditations,
demonstrating professional strength
With its outstanding performance in the industry, Sanyou Bio has
successfully attained six qualifications and two system
certifications, further highlighting its professional expertise and
industry standing. These qualifications include prestigious honors
such as the National High-Tech Enterprise and Specialized, Refined,
Differentiated, and Innovative Enterprise. The system
certifications cover the ISO9001 Quality Management System and GB/T
Intellectual Property Management System, fully demonstrating Sanyou
Bio's rigor and professionalism in quality management and
intellectual property protection.
Summarize
With the official launch of the new 10,000-square-meter research
building, Sanyou Bio has stood at a new starting point. With
greater enthusiasm, firmer beliefs, and more solid steps, the
company will continue to deepen in the field of innovative
biopharmaceutical R&D, enhance the leading advantage of the
super-trillion molecule library, further advance the application of
the super-trillion antibody discovery platform, and expand the "4C"
comprehensive business. We will endeavor to provide global clients
with better quality and more efficient services. Sanyou Bio
believes that in the future, it will join hands with more partners
to co-create a new chapter in the treatment of human diseases
through innovative biological drugs!
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-beginnings-new-journey--sanyou-opening-of-new-10-000-sqm-facility-ushering-in-a-new-era-of-innovation-for-bio-drugs-302261680.html
SOURCE Sanyou Bio